A longitudinal change in DNAm at a CpG site within an intron of HDAC4 was associated with MHD response, while baseline DNAm levels at a CpG in MARK3 were associated with MMD response at 12 weeks. The gene discussed is MARK3; the disease is multiminicore myopathy.